On top of ex­pir­ing Her­ceptin patents, Roche faces huge roy­al­ty loss­es in 2019

We all know some of Roche’s most valu­able patents are ex­pir­ing soon, not the least of which is the huge rev­enue-dri­ver can­cer drug Her­ceptin. But in its lat­est fi­nan­cial up­date, Roche out­lined a dif­fer­ent set of patents that will soon cut hun­dreds of mil­lions from its bal­ance sheet.

In its mid-year earn­ings up­date, Roche warned in­vestors that its “Ca­bil­ly” patents —  which pro­tect a step in the man­u­fac­tur­ing process of cell-based ther­a­pies — would ex­pire in De­cem­ber. For the past 35 years, these patents (grant­ed to Roche’s Genen­tech unit in 1983), have al­lowed Roche to col­lect roy­al­ties from com­peti­tors like Ab­b­Vie, which us­es the process­es to man­u­fac­ture Hu­mi­ra. That drug sold $18.5 bil­lion last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.